CO2017008087A2 - Método para obtener clones celulares de expresión estable de alto rendimiento y moléculas de anticuerpos obtenidas de este modo - Google Patents
Método para obtener clones celulares de expresión estable de alto rendimiento y moléculas de anticuerpos obtenidas de este modoInfo
- Publication number
- CO2017008087A2 CO2017008087A2 CONC2017/0008087A CO2017008087A CO2017008087A2 CO 2017008087 A2 CO2017008087 A2 CO 2017008087A2 CO 2017008087 A CO2017008087 A CO 2017008087A CO 2017008087 A2 CO2017008087 A2 CO 2017008087A2
- Authority
- CO
- Colombia
- Prior art keywords
- recombinant
- protein
- cell clones
- free medium
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un método para recuperar clones de células de mieloma recombinante adaptadas para crecer en medios libres de proteínas. Este procedimiento comprende líneas de células de mieloma recombinante para las que el proceso de adaptación de medio libre de suero a medio libre de proteína no es posible o toma mucho tiempo y se acompaña de la pérdida de producción de anticuerpos debido a la aparición de poblaciones de células no productoras. Los procedimientos incluyen un proceso de adaptación gradual para crecer en medio libre de proteínas a baja y alta densidad celular. La adaptación fenotípica para crecer en medio libre de proteínas a alta densidad celular fue acompañada por un aumento en la velocidad de secreción de la molécula de anticuerpo recombinante y en el porcentaje de clones de células productoras estables. Los clones celulares revelados en la presente invención producen el anticuerpo recombinante humanizado Anti - NeuGcGM3 14F7h. Además, los atributos de identidad de dicho anticuerpo recombinante humanizado anti-NeuGcGM3 14F7 se describen en esta invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510080631.3A CN104651314B (zh) | 2015-02-14 | 2015-02-14 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
PCT/CN2016/076135 WO2016127954A1 (zh) | 2015-02-14 | 2016-03-11 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017008087A2 true CO2017008087A2 (es) | 2017-10-10 |
Family
ID=53242962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0008087A CO2017008087A2 (es) | 2015-02-14 | 2017-08-10 | Método para obtener clones celulares de expresión estable de alto rendimiento y moléculas de anticuerpos obtenidas de este modo |
Country Status (17)
Country | Link |
---|---|
US (1) | US10457747B2 (es) |
JP (1) | JP2018506306A (es) |
KR (1) | KR20180029948A (es) |
CN (1) | CN104651314B (es) |
AU (1) | AU2016218641C1 (es) |
BR (1) | BR112017017303B8 (es) |
CA (1) | CA2974027C (es) |
CO (1) | CO2017008087A2 (es) |
CU (1) | CU20170106A7 (es) |
EA (1) | EA201791828A1 (es) |
IL (1) | IL253932A0 (es) |
MX (1) | MX2017010421A (es) |
MY (1) | MY192147A (es) |
NZ (1) | NZ735485A (es) |
SG (1) | SG11201706595TA (es) |
TN (1) | TN2017000302A1 (es) |
WO (1) | WO2016127954A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
EP3257935A4 (en) * | 2016-03-11 | 2018-08-08 | Biotech Pharmaceutical Co. Ltd. | Method for obtaining high-yield, stable-expression cell clones and antibody molecules obtained thereby |
CN113480652B (zh) * | 2021-07-30 | 2023-04-07 | 成都景泽生物制药有限公司 | 一种重组cho细胞发酵培养生产重组egfr抗体活性分子的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22731A1 (es) | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
GB0208041D0 (en) * | 2002-04-08 | 2002-05-22 | Lonza Biologics Plc | Method of culturing animal cells |
CU23097A1 (es) * | 2002-10-23 | 2005-11-18 | Centro Inmunologia Molecular | Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método |
CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
AU2004286351A1 (en) * | 2003-11-03 | 2005-05-12 | Centocor, Inc. | Method for maintaining low shear in a bioprocessing system |
CU24120B1 (es) * | 2012-03-01 | 2015-08-27 | Ct De Inmunología Molecular | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
CN104152415B (zh) * | 2014-08-13 | 2015-09-30 | 百泰生物药业有限公司 | 获得高产稳定表达重组抗体的骨髓瘤细胞株的方法及应用 |
CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
-
2015
- 2015-02-14 CN CN201510080631.3A patent/CN104651314B/zh active Active
-
2016
- 2016-03-11 MY MYPI2017702967A patent/MY192147A/en unknown
- 2016-03-11 KR KR1020177022618A patent/KR20180029948A/ko not_active Application Discontinuation
- 2016-03-11 CA CA2974027A patent/CA2974027C/en active Active
- 2016-03-11 MX MX2017010421A patent/MX2017010421A/es unknown
- 2016-03-11 US US15/549,087 patent/US10457747B2/en active Active
- 2016-03-11 BR BR112017017303A patent/BR112017017303B8/pt active IP Right Grant
- 2016-03-11 CU CUP2017000106A patent/CU20170106A7/es unknown
- 2016-03-11 WO PCT/CN2016/076135 patent/WO2016127954A1/zh active Application Filing
- 2016-03-11 AU AU2016218641A patent/AU2016218641C1/en active Active
- 2016-03-11 EA EA201791828A patent/EA201791828A1/ru unknown
- 2016-03-11 SG SG11201706595TA patent/SG11201706595TA/en unknown
- 2016-03-11 JP JP2017560865A patent/JP2018506306A/ja active Pending
- 2016-03-11 TN TNP/2017/000302A patent/TN2017000302A1/en unknown
- 2016-03-11 NZ NZ735485A patent/NZ735485A/en active IP Right Revival
-
2017
- 2017-08-09 IL IL253932A patent/IL253932A0/en unknown
- 2017-08-10 CO CONC2017/0008087A patent/CO2017008087A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016218641A1 (en) | 2017-10-05 |
MX2017010421A (es) | 2018-04-26 |
TN2017000302A1 (en) | 2019-01-16 |
CA2974027C (en) | 2021-02-16 |
SG11201706595TA (en) | 2017-09-28 |
BR112017017303B8 (pt) | 2024-03-05 |
US10457747B2 (en) | 2019-10-29 |
AU2016218641C1 (en) | 2020-02-27 |
CA2974027A1 (en) | 2016-08-18 |
CU20170106A7 (es) | 2018-06-05 |
BR112017017303B1 (pt) | 2023-08-08 |
NZ735485A (en) | 2019-08-30 |
AU2016218641B2 (en) | 2019-10-31 |
US20180016353A1 (en) | 2018-01-18 |
EA201791828A1 (ru) | 2017-12-29 |
MY192147A (en) | 2022-08-01 |
WO2016127954A1 (zh) | 2016-08-18 |
IL253932A0 (en) | 2017-10-31 |
KR20180029948A (ko) | 2018-03-21 |
JP2018506306A (ja) | 2018-03-08 |
CN104651314A (zh) | 2015-05-27 |
CN104651314B (zh) | 2018-06-19 |
BR112017017303A2 (pt) | 2018-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017008087A2 (es) | Método para obtener clones celulares de expresión estable de alto rendimiento y moléculas de anticuerpos obtenidas de este modo | |
BR112021011298A2 (pt) | Produção de 3-fucosillactose e lactose por conversão de enzimas alfa-1,3-fucosiltransferase | |
BR112015023036A2 (pt) | método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina | |
AR088252A1 (es) | Produccion de una proteina de interes mediante un promotor regulable de pichia pastoris | |
CL2019002521A1 (es) | Método para producir anticuerpos multiespecíficos. | |
IN2013MU02285A (es) | ||
MX2012012496A (es) | Metodo para producir tetrafluoropropenos. | |
BR112014026308A2 (pt) | composições de cultura celular e métodos para produção de polipeptídeos | |
WO2017051347A3 (en) | Cells and method of cell culture | |
MX2013002657A (es) | Proceso para la produccion de fibrinogeno. | |
BR112017025923A2 (pt) | molécula de ácido nucleico recombinante, molécula de aminoácido recombinante, construto de expressão recombinante, vetor recombinante, micro-organismo recombinante, composição, métodos para produção de um micro-organismo recombinante e para cultivo e crescimento de um micro-organismo geneticamente modificado, uso de uma molécula de ácido nucleico recombinante, e, processo para produção fermentativa de um composto. | |
MX2018004580A (es) | Metodo para producir proteina de fusion con dominio fc de igg. | |
CL2017000402A1 (es) | Anticuerpos anti-vasa y métodos de producción y uso de los mismos | |
SG11202009826PA (en) | Method for large-scale production of lentivirus by using gmp-level serum-free suspension cells | |
MX2013009598A (es) | Composiciones que comprenden alquilalcoxisulfonatos para la produccion de espumas estables a alta temperatura. | |
CO2022007349A2 (es) | Métodos para producir células de epitelio pigmentario retiniano | |
CO6761370A2 (es) | Arn interferentespequeños con secuencias seminales con diana especifica | |
EA201990270A1 (ru) | Смеси, содержащие defi и тауратамиды, и способы их получения | |
MX2021015301A (es) | Métodos de cultivo celular y composiciones para la producción de anticuerpos. | |
BR112018016290A2 (pt) | conjunto de instrumentos de modelagem de nariz, método de produção e um método para modelar o nariz | |
EA202090440A1 (ru) | Улучшенное получение липидов путем ограничения по меньшей мере двух источников лимитирующих питательных веществ | |
ECSP055740A (es) | Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método. | |
CY1118348T1 (el) | Μεθοδος παρασκευης μεταξαλονης | |
CO2023018294A2 (es) | Métodos de nmr para la comparabilidad de estructuras de orden superior de anticuerpos | |
MX2021007366A (es) | Métodos de clarificación de cultivos celulares. |